Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
基本信息
- 批准号:10161378
- 负责人:
- 金额:$ 78.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-09 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
ABSTRACT
The long-term objective of the proposed work is to provide evidenced-based recommendations for minimizing
metabolic adverse events, particularly weight gain, in a diverse population of people living with HIV (PLWH) by
identifying and quantifying variability in drug exposure that may increase risk in patient subgroups. We will
consider a broad array of modifying factors of drug exposure, including demographic characteristics, prior
laboratory values, body anthropometrics, frailty phenotype, and pharmacogenomics. Our focus is on the
integrase strand transfer inhibitors (INSTIs) dolutegravir (DTG) and bictegravir (BIC), as well as tenofovir
alafenamide (TAF). The MWCCS includes diverse PLWH underrepresented in Phase III clinical trials and thus,
in the sponsor-developed population pharmacokinetic models of the drug. In AIM 1, we will enroll diverse PLWH
from four MWCCS sites to collect pharmacokinetic data and further refine the knowledge of factors that influence
DTG, BIC, and TAF pharmacokinetics. Drug concentrations will be measured in blood plasma and peripheral
blood mononuclear cells (TAF only) in the UNC Center for AIDS Research Clinical Pharmacology and Analytical
Chemistry Laboratory (CFAR CPAC). Nonlinear mixed effects models will be used to develop a comprehensive
PK model for each drug of interest. Using these models, then, in AIM 2, we will retrospectively measure drug
concentrations in repository specimens (using the same methods and laboratory as AIM 1, and predict drug
clearance in men and women from initiation of DTG, BIC, and/or TAF. These drug clearances, predicted for
multiple visits per participant, will then be analyzed as the predictors of body weight gain, increased waist to hip
ratio, and increased insulin resistance (as measured by HOMA-IR) over the course of treatment on the drug of
interest, with multiple measures of drug exposure. The hypothesis is that those PLWH with higher drug exposure
(via slower drug clearance) will be more likely to experience the metabolic adverse events of these drugs. Upon
completion, we expect to have the underpinnings of a model-based risk estimator developed for further
prospective validation.
抽象的
拟议工作的长期目标是提供基于证据的建议,以最大程度地减少
代谢不良事件,尤其是体重增加,在艾滋病毒(PLWH)的各种各样的人群中
识别和量化药物暴露的变异性,可能会增加患者亚组的风险。我们将
考虑一系列广泛的药物暴露因素,包括人口统计学,先验
实验室价值,人体人类测量学,脆弱的表型和药物基因组学。我们的重点是
整合酶链转移抑制剂(Instis)DoluteGravir(DTG)和Bictegravir(BIC)以及Tenofovir
Alafenamide(TAF)。 MWCC在III期临床试验中包括多种多样的PLWH,因此
在赞助商开发的该药物的药代动力学模型中。在AIM 1中,我们将注册多样化的PLWH
从四个MWCC站点收集药代动力学数据,并进一步完善有关影响因素的知识
DTG,BIC和TAF药代动力学。药物浓度将在血浆和周围测量
UNC AIDS研究中心研究临床药理学和分析中的血液单核细胞(仅TAF)
化学实验室(CFAR CPAC)。非线性混合效应模型将用于开发全面
每种感兴趣药物的PK模型。然后,使用这些模型,在AIM 2中,我们将回顾性测量药物
存储库标本的浓度(使用与AIM 1相同的方法和实验室,并预测药物
启动DTG,BIC和/或TAF的男女清除。这些药物清除,预计
然后,每个参与者多次访问,然后将分析为体重增加的预测因子,腰部增加到臀部
比率和增加的胰岛素耐药性(通过HOMA-IR测量)在治疗过程中
兴趣,有多种药物暴露量度。假设是那些具有较高药物暴露的PLWH
(通过较慢的药物清除率)将更有可能体验这些药物的代谢不良事件。之上
完成,我们期望开发基于模型的风险估计器的基础,以进一步
潜在验证。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Julie Brumer Dumon...的其他基金
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
- 批准号:1039035410390354
- 财政年份:2021
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
- 批准号:1060085810600858
- 财政年份:2021
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Effects of Aging and Inflammation on Intracellular Nucleoside Reverse Transcriptase Inhibitor Pharmacology in the WIHS Cohort
WIHS 队列中衰老和炎症对细胞内核苷逆转录酶抑制剂药理学的影响
- 批准号:97913189791318
- 财政年份:2018
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with Obesity
基于生理学的药代动力学模型指导肥胖儿童的药物剂量
- 批准号:1045630110456301
- 财政年份:2018
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:82319798231979
- 财政年份:2011
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:88141638814163
- 财政年份:2011
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:81408508140850
- 财政年份:2011
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:86071128607112
- 财政年份:2011
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:84294898429489
- 财政年份:2011
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
相似国自然基金
成人型弥漫性胶质瘤患者语言功能可塑性研究
- 批准号:82303926
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
- 批准号:82302160
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
成人免疫性血小板减少症(ITP)中血小板因子4(PF4)通过调节CD4+T淋巴细胞糖酵解水平影响Th17/Treg平衡的病理机制研究
- 批准号:82370133
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SMC4/FoxO3a介导的CD38+HLA-DR+CD8+T细胞增殖在成人斯蒂尔病MAS发病中的作用研究
- 批准号:82302025
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
融合多源异构数据应用深度学习预测成人肺部感染病原体研究
- 批准号:82302311
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:1068218510682185
- 财政年份:2023
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Ultra-long-acting Biodegradable and Tunable Polymeric Solid Implant for HIV Treatment Maintenance
用于维持艾滋病毒治疗的超长效可生物降解和可调聚合物固体植入物
- 批准号:1075914910759149
- 财政年份:2023
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
- 批准号:1039035410390354
- 财政年份:2021
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
- 批准号:1060085810600858
- 财政年份:2021
- 资助金额:$ 78.4万$ 78.4万
- 项目类别:
Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy
全国结核病预防治疗推广期间每周利福喷丁/异烟肼相关药物不良反应的临床预测
- 批准号:1021733110217331
- 财政年份:2021
- 资助金额:$ 78.4万$ 78.4万
- 项目类别: